Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia

Affiliations

Comment

Christine S Young et al. EBioMedicine. 2015.

. 2015 May 22;2(6):487-8.

doi: 10.1016/j.ebiom.2015.04.020. eCollection 2015 Jun.

¹ Blood Cancer Research Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK.

No abstract available

Comment on

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y, Fu YK, Zhu YM, Lou YJ, Gu ZH, Shi JY, Chen B, Chen C, Zhu HH, Hu J, Zhao WL, Mi JQ, Chen L, Zhu HM, Shen ZX, Jin J, Wang ZY, Li JM, Chen Z, Chen SJ. Shen Y, et al. EBioMedicine. 2015 Apr 12;2(6):563-71. doi: 10.1016/j.ebiom.2015.04.006. eCollection 2015 Jun. EBioMedicine. 2015. PMID: 26285909 Free PMC article.

1. Coombs C.C., Tavakkoli M., Tallman M.S. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304. - PMC - PubMed
1. De B.F., Carafa V., Conte M., Rotili D., Petraglia F., Matarese F. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res. 2014;74(8):2328–2339. (15-4) - PubMed
1. Freireich E.J., Wiernik P.H., Steensma D.P. The leukemias: a half-century of discovery. J. Clin. Oncol. 2014;32(31):3463–3469. (1–11) - PubMed
1. Gale R.E., Hills R., Pizzey A.R., Kottaridis P.D., Swirsky D., Gilkes A.F. The relationship between FLT3 mutation status, biological characteristics and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768–3776. (16-8) - PubMed
1. Sanz M.A., Lo C.F., Martin G., Avvisati G., Rayon C., Barbui T. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253. (15-8) - PubMed